Momelotinib sulfate NEW
| Price | $46 | $77 |
| Package | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-07-23 |
Product Details
| Product Name: Momelotinib sulfate | CAS No.: 1056636-06-6 |
| Supply Ability: 10g | Release date: 2025/07/23 |
Product Introduction
Bioactivity
| Name | Momelotinib sulfate |
| Description | Momelotinib sulfate is an ATP-competitive JAK1/JAK2 inhibitor (IC50: 11 nM/18 nM). It has 10-fold selectivity versus JAK3. |
| In vitro | Momelotinib sulfate inhibits growth of Ba/F3-JAK2V617F and Ba/F3-MPLW515L cells (IC50: 200 nM) or human erythroleukemia (HEL) cells (IC50: 1.5 μM). However, it has considerably less activity against BCR-ABL harboring K562 cells (IC50=58 μM) and FLT3 mutation harboring MV4-11 cells (IC50: 3 μM). Proliferation of parental Ba/F3 cells (Ba/F3-wt) stimulated with IL-3 is inhibited (IC50: 1.4 μM). This is same as the established role of IL-3-dependent signaling in the parental cell line [1]. |
| In vivo | Administering Momelotinib sulfate at doses of 50 and 100 mg/kg had minimal impact on peripheral blood counts over 8 weeks. The median peak plasma concentrations reached 7.1 μM and 32.1μM for the lower and higher doses, respectively, with a 2-hour half-life. Trough levels were observed at 10nM (25 mg/kg) and 900nM (50 mg/kg) 12 hours post-administration. The compound demonstrated high plasma concentrations after oral intake (Cmax= 40.4 μM; Tmax=4 h), suggesting high oral bioavailability. This is likely due to its low blood clearance rate (6.3 mL/min/kg), indicating reduced hepatic first-pass metabolism. In a study, by day 34 post-transplantation, white blood cell counts and hematocrit values in Balb/c mice exceeded the normal range by more than one standard deviation (SD). Subsequent treatment with 25 mg/kg or 50 mg/kg Momelotinib sulfate, or a vehicle control, initiated a rapid decrease in white cell counts within six days and a decrease in hematocrit after 20 days, showing the drug's efficacy in modulating hematologic parameters. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 6.2 mg/mL (10.15 mM), Sonication is recommended. |
| Keywords | Momelotinib sulfate | Momelotinib Sulfate | JAK3 | JAK2 | JAK1 | CYT-387 Sulfate | CYT387 Sulfate | CYT 387 Sulfate |
| Inhibitors Related | Delgocitinib | Deucravacitinib | RO8191 | Ruxolitinib | Tofacitinib Citrate | CEP-33779 | Ruxolitinib phosphate | JAK-IN-10 | Baricitinib | WHI-P97 | Fedratinib | Tofacitinib |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $32.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2025-07-23 | |
| $0.00/10mg |
VIP1Y
|
Moxin Chemicals
|
2025-07-03 | |
| $1520.00/25mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2025-07-16 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY